

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 September 2022 (22.09.2022)



(10) International Publication Number
WO 2022/195008 A1

(51) International Patent Classification:

A61K 9/14 (2006.01) *A61K 38/19* (2006.01)
A61K 9/16 (2006.01) *A61K 38/22* (2006.01)
A61K 9/19 (2006.01) *A61K 39/395* (2006.01)
A61K 38/18 (2006.01) *B33Y 80/00* (2015.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

(21) International Application Number:

PCT/EP2022/056977

(22) International Filing Date:

17 March 2022 (17.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2103785.8 18 March 2021 (18.03.2021) GB

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; Allée de la Recherche, 60, B-1070 Brussels (BE).

(72) Inventors: **MARQUETTE, Sarah**; c/o IP Department, UCB Biopharma SRL, 60 Allée de la Recherche, 1070 Brussels (BE). **GRANDFILS, Christian**; c/o Université of Liege, Centre Interfacultaire des Biomateriaux (CEIB), Institut de Chimie, B6c, Allée du 6 aout 11, 4000 LIEGE (BE). **HURLET, Jerome**; c/o Université of Liege, Centre Interfacultaire des Biomateriaux (CEIB), Institut de Chimie, B6c, Allée du 6 aout 11, 4000 LIEGE (BE).

(74) Agent: **UCB INTELLECTUAL PROPERTY**; C/O UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: FORMULATIONS COMPRISING A THERAPEUTIC PROTEIN AND AT LEAST ONE STABILIZER

(57) Abstract: The invention relates to the field of pharmaceutical compositions comprising proteins as therapeutic active ingredient. More particularly it is directed to di-block or multi-block copolymers used as excipients, and in particular as stabilizer, in protein-containing dried compositions, filaments obtained from these dried compositions, implantable drug delivery device formed from 5 these filaments and to methods of producing such compositions, filaments and devices.



WO 2022/195008 A1